William Navidi
University of Southern California
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by William Navidi.
Proceedings of the National Academy of Sciences of the United States of America | 2002
Irene Tiemann-Boege; William Navidi; Raji P. Grewal; Daniel Cohn; Brenda Eskenazi; Andrew J. Wyrobek; Norman Arnheim
The lifelong spermatogonial stem cell divisions unique to male germ cell production are thought to contribute to a higher mutation frequency in males. The fact that certain de novo human genetic conditions (e.g., achondroplasia) increase in incidence with the age of the father is consistent with this idea. Although it is assumed that the paternal age effect is the result of an increasing frequency of mutant sperm as a man grows older, no direct molecular measurement of the germ-line mutation frequency has been made to confirm this hypothesis. Using sperm DNA from donors of different ages, we determined the frequency of the nucleotide substitution in the fibroblast growth factor receptor 3 (FGFR3) gene that causes achondroplasia. Surprisingly, the magnitude of the increase in mutation frequency with age appears insufficient to explain why older fathers have a greater chance of having a child with this condition. A number of alternatives may explain this discrepancy, including selection for sperm that carry the mutation or an age-dependent increase in premutagenic lesions that remain unrepaired in sperm and are inefficiently detected by the PCR assay.
Pharmacogenetics | 1996
Stephanie J. London; Ann K. Daly; Julian Leathart; William Navidi; Jeffrey R. Idle
CYP2C9 is involved in the metabolism of warfarin and a wide array of other therapeutic agents. It also appears to play a role, along with other cytochrome P450 enzymes, in the metabolism of benzo[a]pyrene, a carcinogen in tobacco smoke. A relatively common allelic variant (termed R144C, Cys144 or more recently CYP2C9*2) has been described that results in the substitution of cysteine for arginine at residue 144 and appears to reduce enzyme activity. We therefore examined the possible association between the presence of the CYP2C9*2 variant allele and risk of lung cancer using peripheral blood DNA from 329 incident cases of lung cancer (152 African-American and 177 Caucasian) and 700 (239 African-American and 461 Caucasian) population controls in Los Angeles County, California. Among the population controls the frequency of the CYP2C9*2 variant allele was lower (p = 0.00002) among African-Americans (0.036) than among Caucasians (0.100). The presence of the CYP2C9*2 variant allele was not associated with a decreased risk of lung cancer; slight but nonstatistically significant elevations in risk were observed for both African-Americans [odds ratio (OR) 1.22, 95% confidence interval (CI) 0.48-3.11] and Caucasians (OR = 1.55, 95% CI 0.96-2.48). The ORs were slightly and nonsignificantly elevated for all histologic types without substantive variation. The association also did not vary materially according to smoking history or whether subjects had the homozygous deletion of the GSTM1 gene. We found no support for the hypothesis that the CYP2C9*2 variant allele decreases the risk of lung cancer. The role of P450s, including CYP2C9, in benzo[a]pyrene metabolism is not fully defined, and CYP2C9 catalyses detoxication as well as activation steps. Thus it is not inconceivable that diminished CYP2C9 activity could increase metabolic activation of benzo[a]pyrene to carcinogenic intermediates. Nonetheless, the small increased risk associated the CYP2C9*2 variant allele in our data is consistent with chance and should not be overinterpreted.
Pharmacogenetics | 1996
Stephanie J. London; Ann K. Daly; Jane Cooper; Catherine L. Carpenter; William Navidi; Li Ding; Jeffrey R. Idle
Genetic polymorphisms in the activation or detoxication of carcinogens, such as those in tobacco smoke, may produce differences in individual susceptibility to lung cancer. The cytochrome P450 CYP2E1 is an enzyme involved in the metabolism of nitrosamines in tobacco smoke. A polymorphism of CYP2E1 detectable by the restriction enzyme Rsa I may be functionally important because it is located in a putative binding site for the transcription factor HNF-1 and has been associated with higher levels of CYP2E1 transcription. It is conceivable that this CYP2E1 Rsa I polymorphism might contribute to differences in susceptibility to lung cancer. We conducted a case-control study of patients with incident lung cancer and population controls in Los Angeles County to examine the association between the CYP2E1 Rsa I polymorphism and lung cancer risk among African-Americans and Caucasians. Samples of white blood cell DNA sufficient for determination of the CYP2E1 Rsa I genotype by a polymerase chain reaction-based assay were obtained from 341 cases and 706 controls with data on lifetime smoking history. No subjects were homozygous for the CYP2E1 Rsa I rare c2 allele. The rare c2 allele was not associated with an increased risk of lung cancer (adjusted odds ratio, OR 0.72; 95% confidence interval, CI = 0.35-1.46). Among the population controls the percentage of subjects carrying the rare c2 allele was lower (p = 0.002) among African-Americans (2%) compared with Caucasians (8%). However, the association between the CYP2E1 Rsa I genotype and lung cancer risk did not differ between ethnic groups. There was no important association between the CYP2E1 Rsa I genotype and lung cancer risk in analyses stratified by cell-type, smoking history, gender, occupational asbestos exposure, and dietary intake of antioxidants vitamin C, vitamin E or beta carotene. Due to the low frequency of the c2 allele in these populations, larger studies would be necessary to rule out a modest association between the CYP2E1 Rsa I polymorphism and lung cancer risk.
Archive | 1991
Norman Arnheim; Honghua Li; Xiangfeng Cui; William Navidi
The polymerase chain reaction (PCR; Saiki et al., 1985, 1988; Mullis and Faloona, 1987) is a method of selective in vitro gene amplification. The principle of the PCR method is shown in Figure 1. Two small stretches of DNA of known sequence that flank the target region to be amplified (Figure la) are used to design two oligonucleotide primers. The synthetically made primers are chosen so that one is complementary to one flanking sequence while the other is complementary to the other flanking sequence. The 3’ hydroxyl ends of the primers face the target sequence. Following DNA denaturation of the target, the single stranded primers hybridize to their complementary flanking sequences (Figure lb). In the presence of a DNA polymerase the primers will be extended through the target sequence (Figure 1c). DNA denaturation, primer hybridization and DNA polymerase extension represent one PCR cycle. If the first cycle is followed by a second one (Figure 1d), more copies of the target sequence will be made.
American Journal of Respiratory and Critical Care Medicine | 1999
John M. Peters; Edward L. Avol; W. James Gauderman; William S. Linn; William Navidi; Stephanie J. London; Helene G. Margolis; Edward B. Rappaport; Hita Vora; Henry Gong; Duncan Thomas
American Journal of Respiratory and Critical Care Medicine | 1999
John M. Peters; Edward L. Avol; William Navidi; Stephanie J. London; W J Gauderman; Fred Lurmann; William S. Linn; Margolis H; Edward B. Rappaport; Henry Gong; Duncan C. Thomas
Journal of the National Cancer Institute | 1995
Stephanie J. London; Ann K. Daly; Jane Cooper; William Navidi; Catherine L. Carpenter; Jeffrey R. Idle
American Journal of Epidemiology | 1996
Susan Preston-Martin; William Navidi; Duncan C. Thomas; Pey-jiuan Lee; Joseph D. Bowman; Janice M. Pogoda
Carcinogenesis | 1997
Stephanie J. London; Ann K. Daly; Julian Leathart; William Navidi; C. C. Carpenter; Jeffrey R. Idle
Cancer Research | 1995
Stephanie J. London; Ann K. Daly; Karen S. Fairbrother; Clair Holmes; Catherine L. Carpenter; William Navidi; Jeffrey R. Idle